Through validation on null intestinal organoids, it was found that inhibition of intestinal Gpr17 expression could promote GLP-1 secretion and thus improve glucose metabolism, suggesting that GPR17 may be a potential interventional target for the treatment of diabetes mellitus (Yan et al., 2022). The gene discussed is GPR17; the disease is diabetes mellitus.